Cadrenal Therapeutics, Inc. Common Stock (CVKD NASDAQ) stock market data APIs
$0.9907
-0.05(-5%)
as of October 6, 2026
Try our APIs with
free plan!
Cadrenal Therapeutics, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Prev. Close
0.9907
Open
0.9408
High
1.0427
Low
0.8945
52 wk Range
0.85-14.4999
Market Cap
3 532 K
Shares Outstanding
3 568 K
EPS
-1.14
Beta
1.95
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Cadrenal Therapeutics, Inc. Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Cadrenal Therapeutics, Inc. Common Stock data using free add-ons & libraries
Get Cadrenal Therapeutics, Inc. Common Stock Fundamental Data
Cadrenal Therapeutics, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -11 651 673
- Earnings Per Share: -4
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Cadrenal Therapeutics, Inc. Common Stock Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-08-13
- EPS/Forecast: -1.16
Get Cadrenal Therapeutics, Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Cadrenal Therapeutics, Inc. Common Stock News
New
Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
Cadrenal Therapeutics Inc. PONTE VEDRA, Fla., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for...
Weekly Buzz: NVS, MRK Win FDA Nod; LLY Snaps Up ATAI; MANE Shines On Hair Loss Data
(RTTNews) - This week, the healthcare sector saw multiple U.S FDA and European Commission approvals, strategic licensing and M&A activity, as well as pivotal clinical trial readouts and regulatory set...
Cadrenal Therapeutics Announces $8.8 Million Private Placement
(RTTNews) - Cadrenal Therapeutics, Inc. (CVKD) has entered into a definitive agreement with a single healthcare-focused institutional investor for a private placement of up to $8.8 million, priced at-...
Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
$3 million upfront with up to approximately $5.8 million of potential additional gross proceeds upon the exercise in full of warrants Net proceeds anticipated to extend cash runway into first quarter...
Get Cadrenal Therapeutics, Inc. Common Stock fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.